People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically significant ... which resulted in losses of 17.5% and 2.4%, respectively. In addition, 33.2% of subjects receiving the ...

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ... in addition to the health benefits already established with ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Semaglutide 2.4 mg is marketed under the brand name Wegovy. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ...

Citing topline data from its STEP-UP Phase 3b study, the Danish drugmaker said that while patients on regular Wegovy at 2. ... placebo experienced 2.4% weight loss. The trial involving more than ...

Participants were randomly assigned to once-weekly semaglutide 7.2 mg, once-weekly semaglutide 2.4 mg (Wegovy ... More detailed results from the STEP UP trial are expected to be presented at ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy ... Step Up trial was conducted to test the efficacy of the higher dose, as the current highest dose available is 2.4 ...